Journal of Molecular Imaging & Dynamics
Open Access

Kain TS

Publications

• Research Article
  Initial Experience of Monitoring Response of Breast Cancer to Bevacizumab-containing Chemotherapy using A New Integrin Specific PET Imaging Tracer [F-18]RGD-K5
  Author(s): Bahri S Bahri S
  
  This study investigates the use of [F-18]RGD-K5, an integrin αvβ3 targeting PET tracer, in breast cancer patients receiving chemotherapy with bevacizumab (Avastin®). Two patients were analyzed: Subject-1 had metastatic breast cancers and Subject-2 had a primary cancer in the breast. The therapy regimen was weekly paclitaxel and carboplatin combined with bi-weekly bevacizumab. Each subject received 5 PET-CT scans: pre-treatment [F-18]RGD-K5 and [F-18]FDG, one [F-18]RGD-K5 F/U scan after 2 doses of bevacizumab, and another [F-18]RGD-K5 and [F-18] FDG F/U after 4 doses of bevacizumab. Many lesions in Subject-1 showed a high [F-18]RGD-K5 baseline uptake. The two most [F-18]RGD-K5 avid lesions had SUVs of 10.8 and 10.1, and the corresponding [F-18]FDG uptakes were much lower (SUV of 1.0 and 3.5). The [F-18]RGD-K5 SUVs in all analyzed lesions decreased during treatment, showi.. View More»
  DOI: 10.4172/2155-9937.1000116

  Abstract PDF

Relevant Topics